With $16.6 million in cash and a quarterly burn rate approaching $7.6 million combined across R&D and G&A, NervGen has roughly two quarters of runway before it needs to raise — and it is simultaneously preparing to initiate a registrational trial in chronic tetraplegia. That tension is the central clinical-strategic reality surrounding the RESTORE study, not the FDA alignment itself, which was expected.
The End-of-Phase 2 agreement matters precisely because chronic tetraplegia has no approved pharmacologic option capable of recovering meaningful function. NVG-291, a PTP-sigma inhibitor designed to relieve the chondroitin sulfate proteoglycan-mediated block on axonal regeneration, targets neural repair rather than symptom management — a mechanistic distinction that shapes every regulatory and endpoint conversation. FDA alignment on study parameters means NervGen and the agency have agreed on what counts as a meaningful treatment effect, which in this population is genuinely hard to define and easy to get wrong. The fact that the biomechanical gait analyses from CONNECT SCI are still ongoing — specifically to distinguish true neural recovery from compensatory movement using coordination, mechanical effort, and postural stability markers — suggests those analyses likely informed the endpoint discussions with FDA. The results, expected this quarter, will either validate or complicate that framework before enrollment begins.
The three leadership hires are not incidental. Shamim Ruff’s background at Sarepta, where she shepherded Exondys 51 through a contested approval in Duchenne muscular dystrophy, is directly relevant to a program likely to face scrutiny over functional endpoint subjectivity. Christine McSherry co-founded the Jett Foundation, which was central to Exondys 51’s approval, and later built outcome measures for rare diseases through Casimir before its acquisition by Emmes. Hiring both signals that NervGen is structuring RESTORE’s patient-focused drug development evidence as a regulatory asset from the outset, not an afterthought.
The number to track is the Q2 2026 biomechanical gait analysis readout from CONNECT SCI. If the blinded analyses confirm genuine neural recovery signatures rather than compensatory adaptation, NervGen enters RESTORE with a validated biomarker framework that could anchor the registrational endpoint and withstand regulatory challenge. If the signal is ambiguous, the agreed-upon study parameters become far harder to defend when primary data arrives.
NVG-291: the facts in one place
- Also written: NVG-291-R
- Sponsor: NervGen Pharma
- Mechanism: Targets chondroitin sulfate proteoglycans (CSPGs) and the inhibitory CSPG-PTPσ pathway to promote neuronal sprouting, remyelination, and a non-inflammatory environment for nervous system repair
- Indication studied: Chronic tetraplegia following spinal cord injury (SCI)
- Phase: Phase 3
- Enrollment: 150
- Primary endpoint: Change from baseline in GRASSP Quantitative Prehension at Week 12
- Headline result: Phase 1b/2a CONNECT SCI study (n=20) met co-primary endpoint: statistically significant three-fold increase in motor connectivity to a hand muscle and statistically significant improvement in gait quality; all NVG-291 subjects classified as responders versus 10% of placebo subjects
- Registry identifier: NCT07799532, NCT05965700
- Current status: Phase 3 RESTORE study (NCT07799532) expected to begin screening September 2026; topline data anticipated first half of 2028
- FDA Fast Track designation: October 23, 2023
- EMA Orphan Drug designation: not dated in summary
- End-of-Phase 2 meeting with FDA alignment announced: April 7, 2026
- Positive blinded biomechanical gait analyses announced: May 26, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
